Zobrazeno 1 - 10
of 509
pro vyhledávání: '"castration-resistant prostate cancer (crpc)"'
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Externí odkaz:
https://doaj.org/article/877b7439e6fb403fbe50735d7b242457
Autor:
Yuanyuan Wang, Jiyuan Chen, Luyao Gong, Yunxia Wang, Aino Siltari, Yan-Ru Lou, Teemu J. Murtola, Shen Gao, Yuan Gao
Publikováno v:
Journal of Nanobiotechnology, Vol 22, Iss 1, Pp 1-19 (2024)
Abstract Resistance to androgen receptor (AR) inhibitors, including enzalutamide (Enz), as well as bone metastasis, are major challenges for castration-resistant prostate cancer (CRPC) treatment. In this study, we identified that miR26a can restore E
Externí odkaz:
https://doaj.org/article/d27180e3a2634eff9bbb371e72a61484
Publikováno v:
Pharmacological Research, Vol 205, Iss , Pp 107234- (2024)
After the initial androgen deprivation therapy (ADT), part of the prostate cancer may continuously deteriorate into castration-resistant prostate cancer (CRPC). The majority of patients suffer from the localized illness at primary diagnosis that coul
Externí odkaz:
https://doaj.org/article/364ce6bf959a46618f61dcba2c1d960b
Publikováno v:
Journal of Urologic Oncology, Vol 21, Iss 3, Pp 257-263 (2023)
Purpose This study aimed to identify predictive factors for the response to abiraterone in patients with high-risk metastatic hormone-sensitive prostate cancer (mHSPC). Materials and Methods This study analyzed the clinical characteristics of 167 pat
Externí odkaz:
https://doaj.org/article/8827b3d2a17a4ff0ab68ccfb98ed1a25
Publikováno v:
OncoImmunology, Vol 12, Iss 1 (2023)
ABSTRACTNew treatment options to battle hormone-refractory prostate carcinoma (PC) are a pressing medical need. Chronic inflammation has been implicated in PC etiology. The pro-inflammatory cytokines IL-6, IL-23 and IL-17 are key mediators to promote
Externí odkaz:
https://doaj.org/article/cc7d291fe74c4869aaf5b9f40ceb7cde
Autor:
Daniel J. Turnham, Manisha S. Mullen, Nicholas P. Bullock, Kathryn L. Gilroy, Anna E. Richards, Radhika Patel, Marcos Quintela, Valerie S. Meniel, Gillian Seaton, Howard Kynaston, Richard W. E. Clarkson, Toby J. Phesse, Peter S. Nelson, Michael C. Haffner, John N. Staffurth, Helen B. Pearson
Publikováno v:
Cells, Vol 13, Iss 8, p 673 (2024)
As the treatment landscape for prostate cancer gradually evolves, the frequency of treatment-induced neuroendocrine prostate cancer (NEPC) and double-negative prostate cancer (DNPC) that is deficient for androgen receptor (AR) and neuroendocrine (NE)
Externí odkaz:
https://doaj.org/article/1e39ec5e9d2d4ad899c5d22bfe802b4a
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
BMC Urology, Vol 22, Iss 1, Pp 1-13 (2022)
Abstract Background Prostate cancer (PCa) is one of the most diagnosed cancers in the world. PCa inevitably progresses to castration-resistant prostate cancer (CRPC) after androgen deprivation therapy treatment, and castration-resistant state means a
Externí odkaz:
https://doaj.org/article/d2be78bb27fc4b8c8618418e9e66fe3a
Publikováno v:
Journal of the Formosan Medical Association, Vol 121, Iss 10, Pp 1929-1937 (2022)
Background: Radium-223 is an alpha-emitting, bone-targeting radiopharmaceutical that confers a survival benefit in patients with confirmed bone-metastatic, castration-resistant prostate cancer with no visceral metastases. We studied real-world use of
Externí odkaz:
https://doaj.org/article/42f2846a1530419d9d18571aa210602b